Title

Evaluation of Antibiotic Use and Duration for Febrile Neutropenia

Authors

Kayla Jensen, CentraCare, Pharmacy
Patricia Aubert, CentraCare, PharmacyFollow
Joy Ward, CentraCare, PharmacyFollow
Ann Wigton, CentraCare, PharmacyFollow

Files

Description

Introduction:

• Febrile neutropenia (FN) affects over 80% of patients with hematologic cancer and 10% to 50% of patients with solid tumors
• National Comprehensive Cancer Network (NCCN) guidelines recommend empiric broad-spectrum monotherapy until the absolute neutrophil count (ANC) is over 500 cells/uL.
• Extended durations with broad-spectrum agents leads to increased risk of antibiotic resistance, toxicity and C. difficile infection.

Purpose

• To evaluate antibiotic prescribing patterns for patients with FN to optimize antibiotic stewardship.

Publication Date

2020

Keywords

Antibiotic stewardship, Febrile neutropenia, Hematologic cancer

Disciplines

Pharmacy Administration, Policy and Regulation | Pharmacy and Pharmaceutical Sciences

Comments

Poster presented at The American Society of Health-System Pharmacists Midyear Meeting, December 6-10, 2020; Virtual Experience

RP-233

Recommended Citation

Jensen, Kayla; Aubert, Patricia; Ward, Joy; and Wigton, Ann, "Evaluation of Antibiotic Use and Duration for Febrile Neutropenia" (2020). Pharmacy Posters. 8.
https://digitalcommons.centracare.com/pharmacy_posters/8